Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Francisco Perez-Miralles"'
Autor:
Sara Gil-Perotin, Jessica Castillo-Villalba, Laura Cubas-Nuñez, Raquel Gasque, David Hervas, Josep Gomez-Mateu, Carmen Alcala, Francisco Perez-Miralles, Francisco Gascon, Jose Andres Dominguez, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background: Neurofilament light chain protein (NFL) and chitinase3-like1 (CHI3L1) have gained importance recently as prognostic biomarkers in multiple sclerosis (MS).Objectives: We aimed to investigate NFL and CHI3L1 cerebrospinal fluid (CSF) profile
Externí odkaz:
https://doaj.org/article/13f821624bc540a8b1285c29b182d2b3
Autor:
Carlos Quintanilla-Bordás, Laura Cubas-Núñez, Jéssica Castillo-Villalba, Sara Carratalá-Boscá, Raquel Gasque-Rubio, Jordi Tortosa-Carreres, Carmen Alcalá, Lorena Forés-Toribio, Celia Lucas, David Gorriz, Francisco Pérez-Miralles, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundSerum neurofilament light chain (sNfL) is a biomarker of neuroaxonal destruction that correlates with acute inflammation (AI) in multiple sclerosis (MS). However, in the treatment era, progression without AI is the main driver of long-term
Externí odkaz:
https://doaj.org/article/67253ab10c5a429da0f649fed3c9eb0c
Autor:
Francisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, Paloma Montero, Jorge Matías-Guiu, Irene Gómez-Estevez, Celia Oreja-Guevara, Sara Gil-Perotín, Yolanda Blanco, María Carcelén, Carlos Quintanilla-Bordás, Lucienne Costa, Luisa Maria Villar, Jose Enrique Martínez-Rodriguez, José Andrés Domínguez, Carmen Calles, Inés González, Javier Sotoca, Agustin Oterino, Celia Lucas-Jimenez, Francisco Pérez-Miralles, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
IntroductionRituximab (RTX) is considered a potential therapeutic option for relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). The main objective of this work was to investigate the effectiveness and safety of rituxim
Externí odkaz:
https://doaj.org/article/a88c93d629e84c54ae63a9bf5ae7db28
Autor:
Jéssica Castillo-Villalba, Sara Gil-Perotín, Raquel Gasque-Rubio, Laura Cubas-Nuñez, Sara Carratalà-Boscà, Carmen Alcalá, Carlos Quintanilla-Bordás, Francisco Pérez-Miralles, Cristina Ferrer, Antonio Cañada Martínez, Jordi Tortosa, Luís Solís-Tarazona, Luisa Campos, Alberto Leivas, Begoña Laíz Marro, Bonaventura Casanova
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Cerebrospinal kappa free light chain (KFLC)-index is a marker of intrathecal immunoglobulin synthesis that aids in the diagnosis of multiple sclerosis (MS). However, little evidence exists on its prognostic role. Our aim is to analyze the relationshi
Externí odkaz:
https://doaj.org/article/b2a1c9817f794ef9b56f12e0b8ea37c3
Autor:
Lamberto Landete, Francisco Pérez-Miralles, Sara García, Antonio Belenguer, Francisco Gascón, Jose Andres Domínguez, María Carcelén-Gadea, Carlos Quintanilla-Bordás, Laura Navarro, Laura Gabaldón, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RRMS–within the so-called platform drugs. It would be desirable to know the ideal drug for each patient. Real clinical practice studies provide us w
Externí odkaz:
https://doaj.org/article/e4c47455c9fb40f4b29c944df0dadf9c
Autor:
José E Meca-Lallana, Jorge Maurino, Francisco Pérez-Miralles, Lucía Forero, María Sepúlveda, Carmen Calles, María L Martínez-Ginés, Inés González-Suárez, Sabas Boyero, Lucía Romero-Pinel, Ángel P Sempere, Virginia Meca-Lallana, Luis Querol, Lucienne Costa-Frossard, Daniel Prefasi, Rocío Gómez-Ballesteros, Javier Ballesteros
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255317 (2021)
BackgroundThe assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific measures. The SymptoMScreen (SyMS) is a patient-reported questionnaire for measuring symptom sev
Externí odkaz:
https://doaj.org/article/189bfa11ecd7489bb2290d28a62384b2
Autor:
Laura Navarro Cantó, Sara Carratalá Boscá, Carmen Alcalá Vicente, Sara Gil-Perontín, Francisco Pérez-Miralles, Jessica Castillo Villalba, Laura Cubas Nuñez, Bonaventura Casanova Estruch
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background and objective: Chronic relapsing inflammatory optic neuritis (CRION) is one of the more common phenotypes related to myelin oligodendrocyte glycoprotein antibodies (MOG-Abs). The absence of specific biomarkers makes distinguishing between
Externí odkaz:
https://doaj.org/article/9a3d3a8eb0c340dbac5a2befb8021d5e
Autor:
Sara Gil-Perotin, Jéssica Castillo-Villalba, Joan Carreres-Polo, Arantxa Navarré-Gimeno, Javier Mallada-Frechín, Francisco Pérez-Miralles, Francisco Gascón, Carmen Alcalá-Vicente, Laura Cubas-Nuñez, Bonaventura Casanova-Estruch
Publikováno v:
Frontiers in Neurology, Vol 9 (2018)
The clinical diagnosis of patients with autoantibodies directed to conformational myelin oligodendrocyte glycoprotein MOG-IgG, can be challenging because of atypical clinical presentation. MOG-IgG seropositivity has been reported in several demyelina
Externí odkaz:
https://doaj.org/article/c6afc20e866a484690af1e431b81a5ff
Autor:
Sunny Malhotra, Marta F Bustamante, Francisco Pérez-Miralles, Jordi Rio, Mari Carmen Ruiz de Villa, Esteban Vegas, Lara Nonell, Florian Deisenhammer, Nicolás Fissolo, Ramil N Nurtdinov, Xavier Montalban, Manuel Comabella
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23634 (2011)
Myxovirus A (MxA), a protein encoded by the MX1 gene with antiviral activity, has proven to be a sensitive measure of IFNβ bioactivity in multiple sclerosis (MS). However, the use of MxA as a biomarker of IFNβ bioactivity has been criticized for th
Externí odkaz:
https://doaj.org/article/085a17e7d2fd4c4385a5efa829cbd86c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.